1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. How will FDA’s LDT Rule Impact Your Laboratory and Patients? Share Your Story!

Do you anticipate the Food and Drug Administration’s (FDA) laboratory-developed test (LDT) final rule creating unnecessary burdens for pathologists or negatively impacting patients’ lives, innovation, or the economy on your community? Your story could be used to help legislators understand how the oversight of tests should be based on protecting patients and providing access to safe diagnostic tests with a framework that is the least burdensome for laboratories.

Fill out the form, and tell us more.

Most Recent Content

  1. CIPI Connections: Pathology Innovation in the Third Dimension
  2. January 23, 2026
  3. House advances bill delaying lab cuts
  4. Utility of Molecular Testing in the Diagnostic Workup of Difficult-to-Classify Tumors
  5. January 20, 2026
  6. View All